

AESKULISA[®]
THE DIAGNOSTIC TOOL THAT WORKS

**INSTRUCTION
MANUAL**

AESKULISA[®] Varicella-Zoster Virus IgA / IgG / IgM
Ref 6051 / 6052 / 6053



Updates	
Current Version	V.004 as of 2021-04-07
Previous Version	V.003 as of 2020-01-20
Update in Section	1; 8.5; 10; 11.1
Reasons for Updates	Update according to IVDR



AESKU.DIAGNOSTICS GmbH & Co. KG
Mikroforum Ring 2
55234 Wendelsheim, Germany
Tel: +49-6734-9622-0
Fax: +49-6734-9622-2222
Info@aesku.com
www.aesku.com

Content

1	Intended Use	3
2	Diagnostic Relevance	3
3	AESKULISA® Test Principle.....	4
4	Antigen	4
5	AESKULISA® Test Components	4
6	Material required, but not provided	5
7	Storage and Stability.....	5
8	AESKULISA® Test Procedure.....	5
8.1	General Directions for Use.....	5
8.2	Preparation of Reagents	6
8.2.1	Microtiter Strips (ready-to-use).....	6
8.2.2	Calibrators (ready-to-use)	6
8.2.3	Controls (ready-to-use)	6
8.2.4	Sample Buffer (5x conc.)	6
8.2.5	Wash Buffer (50x conc.)	6
8.2.6	Anti-Human IgA, IgG or IgM POD Conjugate (ready-to-use).....	6
8.2.7	Substrate (ready-to-use).....	7
8.2.8	Stop Solution (ready-to-use)	7
8.3	Preparation of Samples	7
8.3.1	Sample Material.....	7
8.3.2	Sample Dilution	7
8.3.3	Pre-Absorption of Rheumatoid Factors with AESKULISA® IgM.....	7
8.3.4	Sample Storage.....	7
8.4	Test Performance	8
8.4.1	Pipetting Scheme.....	8
8.4.2	Test Procedure	8
8.5	Automated Test Procedure	10
8.6	CSF Diagnostics	10
9	AESKULISA® Test Evaluation.....	10
9.1	Standardization.....	10
9.2	Quantitative Evaluation	10
9.3	Borderline Range.....	10
9.4	Measurement Range	10
9.5	Qualitative Evaluation	11
9.6	Criteria of Validity.....	11
9.7	Interpretation of Test Results.....	11
10	AESKULISA® Performance Characteristics	12
10.1	Analytical Sensitivity and Specificity.....	12
10.2	Diagnostic Sensitivity and Specificity	12
10.3	Reference Range of Healthy Individuals	13
10.4	Precision.....	13
11	Safety Measures.....	14
11.1	Recommendations and Precautions	14
11.2	Disposal.....	15
12	References	15

1 Intended Use

The *AESKULISA*® Varicella-Zoster Virus IgA, IgG and IgM tests are qualitative and quantitative immunoassays for the demonstration of human IgA, IgG or IgM antibodies in serum or plasma directed against Varicella-Zoster Virus. The *AESKULISA*® Varicella-Zoster Virus IgM test supports the detection of acute infections. The *AESKULISA*® Varicella-Zoster Virus IgG serves for confirmation of a contact with the pathogen and supports in immune status determination. The *AESKULISA*® Varicella-Zoster Virus IgA test is particularly recommended for confirmation of reactivations.

Additionally, the *AESKULISA*® Varicella-Zoster Virus IgA and *AESKULISA*® Varicella-Zoster Virus IgG tests serve for the determination of intrathecally synthesized antibodies in cerebrospinal fluid.

The interpretation of test results has to be considered in combination with the patient's clinical picture. A diagnosis should not be based on the results of the performed test only, but should be made after all clinical and laboratory findings have been evaluated. For confirmation, further investigations should be carried out. *AESKULISA*® immunoassays are designed exclusively for *in vitro* diagnostic use by qualified personnel only, who are trained, specially advised and familiar with the laboratory methods.

2 Diagnostic Relevance

The worldwide distributed Varicella-Zoster Virus (VZV), as well as HSV, CMV and EBV, belong to the human pathogenic *Herpesviridae* family. The pathogen, also named Human Herpes Virus 3 (HHV 3), is the causative agent of chickenpox (Varicella), the characteristic clinical manifestation of an exogenous primary infection, and Herpes Zoster, as the result of an endogenous virus reactivation.

After an incubation time of 10 to 21 days, primary infection in children generally manifests with the characteristic clinical picture of chickenpox (Varicella). Polymorphic exanthemas with a strong itch leading to papules, vesicles and scabs during the different development stages are typical for this children's disease. In contrast, primary infection of adults tend to lead to more severe disease courses often accompanied with complications such as inflammation of the brain (encephalitis), the lung (pneumonia), or the liver (hepatitis). After primary infection the pathogen persists in the spinal and brain ganglia. Following an even long lasting latent phase, declining immunity – often associated with advancing age – may allow the virus to replicate and lead to the clinical picture of Herpes Zoster.

Primary infection during pregnancy is often complicated by a more severe disease progression, in particular pneumonia. Furthermore, transplacental transmission of the virus to the fetus may lead to the congenital Varicella syndrome. The clinical manifestations range in severity and include severe developmental disruption such as skin alterations, neurological disorders, damage to the eyes and skeletal abnormalities. VZV infection late in gestation or immediately following birth may lead to the neonatal Varicella syndrome. Newborns who develop symptoms are at high risk of serious complications associated with the disease.

Attenuated live vaccines have been available for several years. In the case of exposure of susceptible at risk individuals, passive immunization with specific immunoglobulins is administered.

Diagnosis of chickenpox (Varicella) and Herpes Zoster is based primarily on the classical courses of the diseases and their characteristic clinical pictures. For laboratory confirmation, direct and indirect detection methods are available. The indirect detection of both, primary and reactivating Varicella-Zoster Virus infections as well as immune status determination is performed by the serological demonstration of VZV-specific antibodies.

3 AESKULISA® Test Principle

The AESKULISA® (AESKU Enzyme Linked Immunosorbent Assay) is an immunoassay, which is particularly suited to the determination of antibodies. The reaction is based on the specific interaction of antibodies with their corresponding antigen. The test strips of the AESKULISA® microtiter plate are coated with specific antigens of the pathogen of interest. If antibodies in the patient's sample are present, they bind to the fixed antigen. A secondary antibody, which has been conjugated with the enzyme peroxidase, detects and binds to the immune complex. A colorless substrate is then converted into the colored product. The signal intensity of this reaction product is proportional to the antibody activity in the sample and is measured photometrically.

4 Antigen

Antibody detection with AESKULISA® Varicella-Zoster Virus IgA, IgG and IgM immunoassays is based on purified glycoproteins of Varicella-Zoster Virus (strain Ellen).

5 AESKULISA® Test Components

Test Component	Color of Solution	Color of Cap	Pieces / Volume
Break apart microtiter test strips [MP] each with eight antigen coated single wells (altogether 96), 1 frame. The test-specific coating material is inactivated.	-	-	12 pieces
Calibrator A – D [CAL] (ready-to-use) Human serum or chimeric antibody in protein containing solution (BSA); colored; preservative ProClin. The antibody activities of the calibrators are indicated on their labels and on the quality control certificate of the AESKULISA® immunoassay.	yellow*	white	4 x 1,5 ml
Positive Control [CON +] (ready-to-use) Human serum or chimeric antibody in protein containing solution (BSA); colored; preservative ProClin.	yellow*	red	1 x 1,5 ml
Negative Control [CON –] (ready-to-use) Human serum or chimeric antibody in protein containing solution (BSA); colored; preservative ProClin.	yellow*	green	1 x 1,5 ml
Sample Buffer [SB 5x], 5x conc. Protein containing solution (BSA); colored; preservative < 0.1 % sodium azide. The sample buffer of AESKULISA® IgM immunoassays contains Rf absorbent.	IgG, IgA: yellow IgM: green	white	1 x 20 ml
Wash Buffer [WASHB 50x], 50x conc. Solution with tween 20; colored; preservative ProClin.	green	white	1 x 20 ml
Anti-Human IgA, IgG or IgM Conjugate [CONJ] (ready-to-use) Anti-human IgA, IgG or IgM polyclonal antibody, conjugated to horseradish peroxidase, stabilized with protein containing solution (BSA); colored; preservative ProClin.	IgA: red IgG: blue IgM: green	IgA: red IgG: blue IgM: green	1 x 15 ml

Substrate SUB (ready-to-use) Stabilized TMB/H ₂ O ₂ .	colorless	black	1 x 15 ml
Stop Solution STOP (ready-to-use) 1 M Hydrochloric Acid (HCl).	colorless	white	1 x 15 ml
Quality Control Certificate	-	-	1 piece
Instruction for Use	-	-	1 piece

*Color intensity is increasing with antibody activity.

6 Material required, but not provided

- Common laboratory equipment including glassware (cylinder 100 – 1000 ml), test tubes for dilutions, vortex mixer, precision pipettes (10, 100, 200, 500, 1000 µl) or adjustable multipipette (100 – 1000 µl).
- Photometer for microtiter plates with filter, wavelength 450 nm, recommended reference wavelength 600 nm – 690 nm (e.g. 620 nm)
- Microplate washing device (300 µl repeating or multichannel pipette or automated wash system)
- Adsorbent paper
- *Aqua dest.*
AESKULISA® immunoassays are designed to be used with purified water according to the definition of the United States Pharmacopeia (USP 26 - NF 21) and the European Pharmacopeia (Eur. Ph. 4th ed.).

7 Storage and Stability

The microtiter test strips should always be stored with desiccant in the properly sealed aluminum bag. If stored properly in their original containers and at 2 – 8 °C / 35 – 46 °F, all reagents and the microtiter plate are stable – even after opening – until their expiry date indicated on the label. Diluted solutions are stable at 2 – 8 °C / 35 – 46 °F for four weeks.

8 **AESKULISA®** Test Procedure

8.1 General Directions for Use

Optimum results can only be achieved if the instructions are strictly followed. Only use **AESKULISA®** reagents when using **AESKULISA®** immunoassays. The test components must not be exchanged for reagents of other manufacturers.

Microtiter plates, calibrators, controls and conjugates of **AESKULISA®** immunoassays are test- and lot-specific and must not be used in other lots. The evaluations of the calibrators and controls are indicated on the quality control certificate provided with the **AESKULISA®** test kit. Washing solution, substrate and stop solution can be used for all **AESKULISA®** immunoassays irrespective of lot and test.

The sample buffer of the *AESKULISA*® IgA and IgG immunoassays can be used for all *AESKULISA*® IgA and IgG immunoassays (REF 6xxx) irrespective of lot and test. The sample buffer of the *AESKULISA*® IgM immunoassays contains Rf absorbent and can be used for all *AESKULISA*® IgM immunoassays for the diagnosis of infectious diseases (REF 6xxx) irrespective of lot and test.

To avoid contamination, aseptic techniques should be used when removing aliquots from the reagent tubes. Conjugate and substrate solution should never be pipetted with tips that are contaminated with other reagents. Reproducibility of test results is dependent on thorough homogenization of the reagents. Therefore, reagent and sample dilutions should be agitated before use. Inappropriate dilution may result in a loss of sensitivity.

Be sure to pipette carefully and comply with the given incubation times and temperatures. Adequate washing avoids test unspecificities.

Avoid the exposure of reagents to strong light during storage and incubation. Never allow the test components to reach temperatures higher than 37 °C / 99 °F. Reagents must be tightly closed after use to avoid evaporation and contamination. Take care to not mix-up the caps of the vials. The test components must not reach temperatures above 37 °C.

AESKULISA® immunoassay test runs are only valid if the validation criteria are fulfilled.

8.2 Preparation of Reagents

All components and the microtiter plate must be brought to room temperature (20 – 25 °C / 68 – 77 °F) before use. Liquid reagents must be mixed thoroughly. For the dilution of buffer concentrates only clean glass ware must be used.

8.2.1 Microtiter Strips (ready-to-use)

The microtiter test strips are labeled with abbreviations for the coated antigen.

8.2.2 Calibrators (ready-to-use)

The calibrators CAL A – CAL D are ready-to-use and must not be diluted any further. Calibrators must be used for each test run, independent of the number of microtiter test strips to be used.

8.2.3 Controls (ready-to-use)

The positive control CON+ and the negative control CON– are ready-to-use and must not be diluted any further. Controls must be used for each test run, independent of the number of microtiter test strips to be used.

Depending on national guidelines, laboratories can also validate their own controls and use them alternatively.

8.2.4 Sample Buffer (5x conc.)

The concentrated sample buffer is to be diluted 1:5 with distilled water prior to use (e. g. 20 ml + 80 ml). The sample buffer of *AESKULISA*® IgM immunoassays contains Rf absorbent.

8.2.5 Wash Buffer (50x conc.)

The concentrated wash buffer is to be diluted 1:50 with distilled water prior to use (e. g. 20 ml + 980 ml).

8.2.6 Anti-Human IgA, IgG or IgM POD Conjugate (ready-to-use)

The conjugate is ready-to-use.

8.2.7 Substrate (ready-to-use)

The TMB substrate must always be pipetted with brand new tips in order to avoid contamination. Avoid intense exposure of TMB solution to light.

8.2.8 Stop Solution (ready-to-use)

The stop solution is ready-to-use.

8.3 Preparation of Samples

8.3.1 Sample Material

The use of freshly collected serum or EDTA plasma samples is recommended. Icteric, lipemic, hemolytic or bacterially contaminated samples should not be used. Samples with particles should be cleared by centrifugation (< 1000 x g). The supernatant should be taken off and used for further analysis. Samples must not be thermally inactivated.

8.3.2 Sample Dilution

The samples are to be diluted 1:101 (e. g. 10 µl + 1000 µl) with 1x sample buffer and mixed thoroughly.

8.3.3 Pre-Absorption of Rheumatoid Factors with AESKULISA® IgM

Rheumatoid factors (Rf) are autoantibodies mainly of the IgM class, which preferably bind to IgG immune complexes. The demonstration of pathogen-specific IgM antibodies might lead to false-positive test results by the presence of such unspecific rheumatoid factors. Furthermore weak-binding pathogen-specific IgM antibodies might be displaced by stronger-binding IgG antibodies leading to false-negative IgM test results. Therefore, the sample buffer of AESKULISA® IgM immunoassays contains a specific Rf absorbent. Rf absorption is performed by dilution of the patient's sample in 1x dilution buffer of the AESKULISA® IgM immunoassay and subsequent incubation for a **minimum of 15 minutes at room temperature**.

8.3.4 Sample Storage

Patient samples should be used within 8 hours, respectively stored tightly closed at 2 – 8 °C / 35 – 46 °F up to 48 hours. Extended storage is possible at ≤ -20 °C / -4 °F. Avoid repeated freezing and thawing.

8.4 Test Performance




8.4.1 Pipetting Scheme









Depending on the intended quantitative or qualitative test evaluation when using AESKULISA® immunoassays, the following pipetting scheme is recommended:

	Quantitative Evaluation					Qualitative Evaluation			
	1	2	3	4		1	2	3	4
A	CAL A	P3			A	CON-	P5		
B	CAL B	P4			B	CAL B	P6		
C	CAL C	P5			C	CAL B	...		
D	CAL D	P6			D	CON+			
E	CON-	...			E	P1			
F	CON+				F	P2			
G	P1				G	P3			
H	P2				H	P4			
	CAL A	Calibrator A				CON-	Negative Control		
	CAL B	Calibrator B				CAL B	cut off Control		
	CAL C	Calibrator C				CON+	Positive Control		
	CAL D	Calibrator D							
	CON-	Negative Control							
	CON+	Positive Control							

8.4.2 Test Procedure

Place the required number of cavities in the frame and prepare a protocol sheet.
 For manual use processing at room temperature is recommended.

Step	Symbol	Description
1. Addition of calibrators, controls, and diluted samples		Addition of each 100 µl ready-to-use calibrators, controls and diluted samples into the appropriate wells.
2. Sample incubation		Incubation for 30 +/- 3 minutes at 20 – 32 °C / 68 – 89 °F.
3. 3 x Wash		Aspirate the solution, fill each well with 300 µl 1x wash buffer, aspirate the washing solution and repeat the washing procedure another two times; dry by tapping the microtiter plate on a paper towel.

<p>4. Addition of conjugate</p>		<p>Addition of each 100 µl ready-to-use conjugate solution into the appropriate wells.</p>
<p>5. Conjugate incubation</p>		<p>Incubation for 30 +/- 3 minutes at 20 – 32 °C / 68 – 89 °F.</p>
<p>6. 3 x Wash</p>		<p>Aspirate the solution, fill each well with 300 µl 1x wash buffer, aspirate the washing solution and repeat the washing procedure another two times; dry by tapping the microtiter plate on a paper towel.</p>
<p>7. Addition of substrate</p>		<p>Addition of each 100 µl ready-to-use substrate solution into the appropriate wells.</p>
<p>8. Substrate incubation</p>		<p>Incubation for 30 +/- 3 minutes at 20 – 32 °C / 68 – 89 °F. Avoid exposure to strong light.</p>
<p>9. Addition of stop solution</p>		<p>Addition of each 100 µl ready-to-use stop solution into the appropriate wells using the same order as pipetting the substrate.</p>
<p>10. Incubation</p>		<p>Optional: Incubation for 5 minutes.</p>
<p>11. Agitation</p>		<p>Agitate the microtiter plate carefully for 5 seconds.</p>
<p>12. Analysis</p>	 <p>450/620 nm</p>	<p>Read optical density (OD) within 30 minutes at 450 nm against a recommended reference wavelength of 620 nm.</p>

8.5 Automated Test Procedure

The automated processing of *AESKULISA*® immunoassays is performed analogous to manual use. The specified test procedure must be adhered to. The *AESKULISA*® immunoassays are evaluated for use with a range of different instruments; the corresponding assayfiles are available on request. For automated processing of *AESKULISA*® immunoassays on other instruments, evaluation of assayfiles by the test kit supplier in collaboration with and instrument provider is recommended. The correct automated processing of *AESKULISA*® immunoassays must finally be validated by the user.

8.6 CSF Diagnostics

The *AESKULISA*® Varicella-Zoster Virus IgA and *AESKULISA*® Varicella-Zoster Virus IgG tests serve for the determination of intrathecally synthesized antibodies in cerebrospinal fluid. The test procedure is described in a separate instruction for use, which is available on request.

9 *AESKULISA*® Test Evaluation

9.1 Standardization

The *AESKULISA*® Varicella-Zoster Virus IgG immunoassay has been standardized using the International Standard Preparation W1044 of the World Health Organization (WHO) as a reference. Quantitative test results are expressed in mIU/ml. Calibration of the *AESKULISA*® Varicella-Zoster Virus IgA and IgM tests was performed using internal reference sera. Quantitative test results are expressed in U/ml.

9.2 Quantitative Evaluation

Generally, the quantitative data evaluation is recommended when using *AESKULISA*® immunoassays. For generation of a standard curve, the optical measurement signals (optical density, OD) of the calibrators are plotted against their antibody activity (in IU/ml or U/ml). The antibody activities of the calibrators are indicated on the lot-specific quality control certificate provided with the *AESKULISA*® test kit. For optimal results, log/lin coordinates and a 4-parameter logistic (4 PL) fit is recommended. Using the generated curve, antibody activities of the samples can be directly evaluated from the optical measurement signals.

9.3 Borderline Range

The borderline range of the *AESKULISA*® immunoassay is specified on the quality control certificates provided with the test kit and indicate the range of borderline test results. Values below this range indicate a negative test result; values above the borderline range are interpreted positive. As a consequence of different seroprevalences and vaccination programs in individual countries, we recommend to verify the borderline range by own analysis and adapt if necessary.

9.4 Measurement Range

The measurement range of the *AESKULISA*® immunoassay is specified on the quality control certificate provided with the test kit. The linearity of dilution as well as a high precision and reproducibility of test results has been demonstrated within this range in comprehensive evaluation studies. Samples with test results above the upper limit of quantification should be reported as >max. Samples with test results below the lower limit of quantification should be reported as <min. In case a patient sample shows a test result above the upper limit of quantification, the sample may be tested at a higher dilution. The resulting antibody activity must then be multiplied by the additional dilution factor.

9.5 Qualitative Evaluation

The qualitative data evaluation when using AESKULISA® immunoassays is performed by comparison of the optical measurement signal (optical density, OD) of the patient's sample with the mean optical measurement signal of the calibrator B (cut off calibrator CAL B) tested in duplicate. If the patient's sample reaches OD values within the borderline range of +/- 20 % around the mean OD of the cut off calibrator CAL B, the sample is considered as equivocal. Samples with higher OD values are evaluated as positive, samples with lower OD values are evaluated as negative.

9.6 Criteria of Validity

The following criteria of validity have to be fulfilled for a valid test run:

- OD CAL A < 0.3
- OD CAL A < OD CAL B < OD CAL C < OD CAL D
- OD CAL D > 1.3
- The negative control must be evaluated as negative.
- The positive control must not be evaluated as negative.
- By use of quantitative AESKULISA® immunoassays, the positive control must present an antibody activity within the validity range indicated on the quality control certificate of the AESKULISA®.
- By use of qualitative AESKULISA® immunoassays, the variation of the OD values of the cut off calibrator B, tested in duplicate, must not be higher than 20 %.

If these criteria are not met, the test is not valid and must be repeated.

In case of an invalid test run, the expiration dates of the (ready-to-use) reagents, the storage conditions, the incubation times and temperatures, the pipettes, the washer incl. washing cycles, the photometer as well as other devices used should be verified. If no explicable cause for an invalid test run or other aberrant results can be identified, please contact the supplier or manufacturer of the test kit.

9.7 Interpretation of Test Results

A positive test result in AESKULISA® immunoassays confirms the presence of specific antibodies. A negative result indicates that no clinically relevant antibody activity against the pathogen are present in the patient's sample, but does not exclude the possibility of an acute infection. In case of a borderline result, a reliable evaluation is not possible. A definitive diagnosis can only be achieved by testing paired serum samples, taken at one to two week intervals, in parallel.

A primary infection manifesting as chickenpox is generally accompanied by the formation of IgM and IgG antibodies and a seroconversion. In some cases, IgA antibodies also become detectable. Whereas IgA and the IgM antibodies disappear within a few weeks after primary infection, the IgG antibody activity generally persists life-long to provide immunity. In cases of reactivation of the virus inducing the clinical picture of Herpes Zoster, the IgG and – in many cases – also the IgA antibody activity rise rapidly within a few days after onset of the disease, whereas IgM antibodies may not be detectable. IgA antibodies directed against Varicella-Zoster Virus may also be observed in patients with latent VZV infection.

Immune status determination and vaccination control – in particular in immunodeficient individuals – is generally based on the demonstration of VZV-specific IgG antibodies. Particularly IgG antibodies directed against VZV-specific glycoproteins are correlated with immune protection.

Basic Interpretation Scheme of Serological Test Results

IgM Activity	IgG Activity	IgA Activity	Evaluation
negative	negative	negative	No specific antibodies detectable. In case of reasonable suspicion, another test in one or two weeks is recommended.
positive	positive	negative / positive	Indication of acute infection. For confirmation, further investigations are recommended.
negative / positive	positive	positive	Indication of reactivation. For confirmation, further investigations are recommended.
negative	positive	negative	Indication of a past infection / latency.

The interpretation of test results has to be considered in combination with the patient's clinical picture. A diagnosis should not be based on the results of the performed test only, but should be made after all clinical and laboratory findings have been evaluated. For confirmation, further investigations should be carried out.

10 AESKULISA® Performance Characteristics

10.1 Analytical Sensitivity and Specificity

The Limit of Blank (LoB) was assessed by multiple analysis of wells containing sample buffer only. The Limit of Detection (LoD) was assessed by multiple analysis of negative samples.

	Limit of Blank (LoB)	Limit of Detection (LoD)
AESKULISA® Varicella-Zoster Virus IgA	0.35 U/ml	0.95 U/ml
AESKULISA® Varicella-Zoster Virus IgG	1.74 mIU/ml	2.09 mIU/ml
AESKULISA® Varicella-Zoster Virus IgM	0.83 U/ml	2.19 U/ml

The analytical specificity of the AESKULISA® immunoassays was assessed by addition of potentially interfering substances to samples and determination of their influence on the measurement. A significant influence of hemoglobin (up to 800 mg/dl), bilirubin (up to 20 mg/dl), bilirubin conjugate (up to 20 mg/dl) and triglycerides (up to 3000 mg/dl) on test results was not observed.

10.2 Diagnostic Sensitivity and Specificity

Sensitivity and specificity of the AESKULISA® Varicella-Zoster Virus IgA, IgG and IgM immunoassays were assessed by the analysis of more than 160 serum samples from healthy blood donors and individuals with suspected Varicella-Zoster Virus infection each using the Varicella-Zoster Virus IgA, IgG and IgM ELISA immunoassays of leading European manufacturers as reference tests.

	Sensitivity	Specificity
AESKULISA® Varicella-Zoster Virus IgA	> 99 %	90.5 %
AESKULISA® Varicella-Zoster Virus IgG	> 99 %	> 99 %
AESKULISA® Varicella-Zoster Virus IgM	> 99 %	> 99 %

Sera classified as borderline were not included in the calculation of sensitivity and specificity.

10.3 Reference Range of Healthy Individuals

Testing of serum samples from unselected blood donors with AESKULISA® Varicella-Zoster Virus IgA, IgG and IgM immunoassays resulted in the following distribution:

AESKULISA®	Nr. of Samples	Negative	Borderline	Positive
Varicella-Zoster Virus IgA	100	96 (96.0 %)	2 (2.0 %)	2 (2.0 %)
Varicella-Zoster Virus IgG	100	2 (2.0 %)	2 (2.0 %)	96 (96.0 %)
Varicella-Zoster Virus IgM	100	99 (99.0 %)	1 (1.0 %)	0 (0.0 %)

10.4 Precision

Precision and reproducibility of test results obtained with AESKULISA® Varicella-Zoster Virus IgA, IgG and IgM were assessed by the determination of the intra- and interassay precision as well as the lot-to-lot variance by the analysis of multiple samples of different antibody activities.

AESKULISA® Varicella-Zoster Virus IgA

Sample	Extinction (OD)	IgA Activity	Intraassay CV (U/ml)	Interassay CV (U/ml)	Lot-to-Lot CV (U/ml)
Serum 1	0.228	4.4 U/ml	7.0 %	9.3 %	13.1 %
Serum 2	0.418	9.2 U/ml	5.6 %	8.8 %	5.8 %
Serum 3	0.579	13.8 U/ml	5.5 %	9.1 %	7.5 %
Serum 4	0.722	18.8 U/ml	5.6 %	8.7 %	11.7 %
Serum 5	0.983	30.6 U/ml	9.7 %	11.2 %	20.4 %

AESKULISA® Varicella-Zoster Virus IgG

Sample	Extinction (OD)	IgG Activity	Intraassay CV (mIU/ml)	Interassay CV (mIU/ml)	Lot-to-Lot CV (mIU/ml)
Serum 1	0.335	54.8 mIU/ml	4.0 %	5.4 %	6.6 %
Serum 2	0.563	107.7 mIU/ml	4.7 %	5.9 %	8.1 %
Serum 3	1.024	261.5 mIU/ml	4.3 %	4.4 %	10.6 %
Serum 4	1.324	409.8 mIU/ml	4.4 %	5.0 %	4.6 %
Serum 5	1.794	829.2 mIU/ml	5.4 %	7.1 %	8.4 %

AESKULISA® Varicella-Zoster Virus IgM

Sample	Extinction (OD)	IgM Activity	Intraassay CV (U/ml)	Interassay CV (U/ml)	Lot-to-Lot CV (U/ml)
Serum 1	0.210	4.9 U/ml	3.0 %	8.1 %	10.1 %
Serum 2	0.318	7.8 U/ml	4.7 %	12.9 %	17.4 %
Serum 3	0.406	10.5 U/ml	6.7 %	8.2 %	8.3 %
Serum 4	1.085	33.4 U/ml	12.7 %	19.7 %	20.9 %
Serum 5	2.655	139.2 U/ml	10.3 %	12.6 %	9.9 %

More comprehensive study reports on additional performance characteristics such as analytical sensitivity, analytical specificity, trueness, precision, accuracy, recovery, linearity, limits of detection and measurement range are available on request.

11 Safety Measures

11.1 Recommendations and Precautions

AESKULISA® immunoassays are designed exclusively for *in vitro* diagnostic use by qualified personnel only, who are trained, specially advised and familiar with the laboratory methods. All kit reagents and human specimens should be handled carefully, using established good laboratory practice. If the product is damaged or product information - including the labelling - is wrong or incorrect, please contact the manufacturer or supplier of the test kit.

Do not pipette by mouth. Do not smoke, eat or drink in areas in which specimens or kit reagents are handled. Avoid direct contact by wearing disposable gloves, laboratory coat and safety glasses while handling kit reagents or specimens. Wash hands thoroughly afterwards.

This product contains dilutions of human serum samples. Although all serum samples have been tested and found negative for anti-HIV 1 and 2-ab, HBs-Ag (Hepatitis B-Virus-surface Antigen) and anti-HCV-ab, they should be considered potentially infectious. This product contains dilutions of animal origin. Please observe the relevant statutory requirements.

This kit contains potentially hazardous components, which might be irritant to eyes and skin.

Individual test components contain sodium azide (NaN₃) as a preservative. Sodium azide may be toxic if ingested or adsorbed by skin or eyes. Sodium azide may react with lead and copper plumbing to form highly explosive metal azides. On disposal, flush with a large volume of water to prevent azide build-up.

Calibrators and controls as well as patient samples should be considered potentially infectious and handled according to national laws. Patient samples and other potentially infectious material should be decontaminated after the test run.

Reagents should be stored safely and be inaccessible to children.

Any serious incident that has occurred in relation to the device shall be reported to the manufacturer and the competent authority of the member state in which the user and/or the patient is established.

A summary of Safety and Performance is available via Eudamed as well as upon request.

11.2 Disposal

For decontamination and disposal please follow the recommendations of the CDC as well as the relevant local and national statutory requirements.

12 References

Hammond, O., Wang, Y., Green, T., Antonello, J., Kuhn, R., Motley, C., Stump, P., Rich, B., Chirmule, N., Marchese, R.D.(2006) The optimization and validation of the glycoprotein ELISA assay for quantitative varicella-zoster virus (VZV) antibody detection. *J. Med. Virol.* 78, 1679 – 87.

Robert-Koch Institut (2001) Mitteilung der Ständigen Impfkommision (STIKO) am Robert Koch-Institut: Fragen und Antworten zu verschiedenen Impfungen. *Epidemiologisches Bulletin* 8, 58 – 9.

Sauerbrei, A. (2014) Varicella-Zoster Virus. AWMF-Leitlinie zur Labordiagnostik schwangerschaftsrelevanter Virusinfektionen.

Sauerbrei, A. (2016) Diagnosis, antiviral therapy, and prophylaxis of varicella-zoster virus infections. *J. Clin. Microbiol. Infect. Dis.* 35, 723 – 34.

Sauerbrei, A. and Wutzler, P. (2007) Herpes simplex and varicella-zoster virus infections during pregnancy: current concepts of prevention, diagnosis and therapy. Part 2: Varicella-zoster virus infections. *Med. Microbiol. Immunol.* 196, 95 – 102.

Simboli sulle etichette / Symbols on labels / Symboles sur étiquettes / Símbolos sobre las etiquetas / Symbole auf den Etiketten / Σύμβολα στις ετικέτες / Símbolos nos rótulos



Diagnosi in vitro, For in vitro diagnostic use, Pour diagnostic in vitro, Para uso diagnóstico in vitro, In Vitro Diagnostikum, In Vitro Διαγνωστικό μέσο, Para uso Diagnóstico in vitro



Numero d'ordine, Catalogue number, Référence Catalogue, Numéro de catálogo, Bestellnummer, Αριθμός παραγγελίας, Número de catálogo



Descrizione lotto, Lot, Lot, Lote, Chargen Bezeichnung, Χαρακτηρισμός παρτίδας, Lote



Conformità europea, EC Declaration of Conformity, Déclaration CE de Conformité, Declaración CE de Conformidad, Europäische Konformität, Ευρωπαϊκή συμφωνία, Declaração CE de Conformidade



96 determinazioni, 96 tests, 96 tests, 96 pruebas, 96 Bestimmungen, 96 προσδιορισμοί, 96 Testes



Rispettare le istruzioni per l'uso, See instructions for use, Voir les instructions d'utilisation, Ver las instrucciones de uso, Gebrauchsanweisung beachten, Λάβετε υπόψη τις οδηγίες χρήσης, Ver as instruções de uso



Da utilizzarsi entro, Use by, Utilise avant le, Utilizar antes de, Verwendbar bis, Χρήση μέχρι, Utilizar antes de



Conservare a 2-8°C, Store at 2-8°C (35-46°F), Conserver à 2-8°C, Conservar a 2-8°C, Lagerung bei 2-8°C, Φυλάσσεται στους 2-8°C, Conservar entre 2-8°C



Prodotto da, Manufactured by, Fabriqué par, Fabricado por, Hergestellt von, Κατασκευάζεται από, Fabricado por



Calibratore cut-off, Cut off Calibrator, Etalon Seuil, Calibrador de cut-off, Grenzwert Kalibrator, Οριακός ορός Αντιδραστήριο αθμονόμησης, Calibrador de cut-off



Controllo positivo, Positive Control, Contrôle Positif, Control Positivo, Positiv Kontroll, Θετικός ορός ελέγχου, Controllo positivo



Controllo negativo, Negative Control, Contrôle Négatif, Control Negativo, Negativ Kontrolle, Αρνητικός ορός ελέγχου, Controllo negativo



Calibratore, Calibrator, Etalon, Calibrador, Kalibrator, Αντιδραστήριο βαθμονόμησης, Calibrador



Recupero, Recovery, Corrélation, Recuperado, Wiederfindung, Ανάκτηση, Recuperação



Coniugato, Conjugate, Conjugé, Conjugado, Konjugat, Σύζευγμα, Conjugado,

MP

Micropiastra rivestita, Coated microtiter plate, Microplaque sensibilisée, Microplaca sensibilizada, Beschichtete Mikrotiterplatte, Επικαλυμμένη μικροπλάκα, Microplaca revestida

WASHB

Tampone di lavaggio, Wash buffer, Tampon de Lavage, Solución de lavado, Waschruffer, Ρυθμιστικό διάλυμα πλύσης, Solução de lavagem

SUB

Tampone substrato, Substrate buffer, Substrat, Tampón sustrato, Substratpuffer, Ρυθμιστικό διάλυμα υποστρώματος, Substrato

STOP

Reagente bloccante, Stop solution, Solution d'Arrêt, Solución de parada, Stopreagenz, Αντιδραστήριο διακοπής αντίδρασης, Solução de paragem

SB

Tampone campione, Sample buffer, Tampon Echantillons, Tampón Muestras, Probenpuffer, Ρυθμιστικό διάλυμα δειγμάτων, Diluente de amostra